- Among patients with type 2 diabetes on sodium-glucose cotransporter-2 inhibitors, 6.4% developed a urinary tract infection, with 8% classified as severe.
- Urinary tract infection (UTI) occurrence was linked to a more than 3 times higher risk of major adverse cardiovascular events, including heart failure, stroke, and myocardial infarction.
- Patients with UTI had over a 2 times greater risk of significant kidney complications or renal failure.
- Stopping sodium-glucose cotransporter-2 inhibitors after a UTI increased cardiovascular and all-cause mortality by 40% to 50% without reducing recurrent UTI risk.
- Continuing sodium-glucose cotransporter-2 inhibitor therapy, when appropriate, may preserve cardiovascular and renal benefits despite infection history.
Source: European Heart Journal
